The need for neuropsychiatry clinical trials to evolve is crucial. Traditional measures lack sensitivity, elevating the need for novel, objective measures of drug target engagement to offset or combat placebo effects. Additionally, the impact of neuropsychiatric conditions on cognition has gained broad interest across the pharmaceutical industry. This webinar highlights the latest advances in neurotech, which enable the collection of real-world objective data, and features key findings from a Phase Ib study presented at the 38th European College of Neuropsychiatry (ECNP) annual meeting.
One example of this evolving landscape is a clinical-stage neuroscience program advancing DLX-001 (zalsupindole), a novel neuroplastogen in development for the treatment of major depressive disorder. The broader therapeutic approach centers on neuroplasticity-promoting compounds intended to address treatment-resistant neuropsychiatric and neurological conditions.
The featured speakers in this webinar will showcase data demonstrating the power of EEG for measuring drug target engagement and cognition in a clinical trial for major depressive disorder, an area with continued unmet clinical need.
Register today to learn how sensitive, objective, real-world data collection can accelerate the evolution of neuropsychiatric clinical trials and the clinical development of effective CNS therapies to improve the lives of millions of people living with neuropsychiatric conditions.
Keywords: Clinical Development, Clinical Research, Clinical Trial Design, Clinical Trials, CNS, CRO, Digital Endpoints, Drug Development, Drug Target, EEG, Major Depressive Disorder, Neuropsychiatry, Therapeutic Areas